

We thank the reviewers for reviewing our paper. In the following, we provide a detailed account of all the changes that we have made in the revised version of the paper. We would like to thank all the reviewers for their thoughtful and constructive remarks.

Reviewer #1:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Minor revision

Specific Comments to Authors: This manuscript is scientifically well done and overall well written. In some ways it is a shame that the authors did not find more targetable mutations which could be of benefit to this population of patients. I have a few minor comments to make the manuscript easier for readers who are not as familiar with gene sequencing and profiling to understand. Abstract, Methods line 3: Please define SNVs at first use Abstract, Conclusions, line 3: I recommend deleting the word “slightly” since in other places, such as the Core Tip, the authors simply say “enriched” Introduction, second paragraph, line 7: TCGA is The Cancer Genome Atlas; line 12, please define dMMR at first use Introduction, third paragraph, line 2: laRotrectinib is misspelled M&M, Mutational Profiling, first paragraph, second to last line: Please add “more THAN 25% OF regions” M&M, Mutational Profiling, second paragraph, line 5: Please define MSS as first use Results, Novel Fusions, line 7: Please define IGV at first use Discussion, second paragraph, line 5: Please delete the word “Although”

“Abstract, Methods line 3: Please define SNVs at first use” Thanks, we have fixed the error.

“Conclusions, line 3: I recommend deleting the word “slightly” since in other places, such as the Core Tip, the authors simply say “enriched” ” Thanks, We have changed the wording in the text.

“Introduction, second paragraph, line 7: TCGA is The Cancer Genome Atlas; line 12, please define dMMR at first use Introduction, third paragraph, line 2: laRotrectinib is misspelled” Thanks, we have fixed the error.

“Mutational Profiling, first paragraph, second to last line: Please add “more THAN 25% OF regions” M&M, Mutational Profiling, second paragraph, line 5: Please define MSS as first use” Thanks, we have fixed the error.

“Results, Novel Fusions, line 7: Please define IGV at first use Discussion, second paragraph, line 5: Please delete the word “Although” ” Thanks, we have fixed the error.

Reviewer #2:

Scientific Quality: Grade B (Very good)

Language Quality: Grade B (Minor language polishing)

Conclusion: Accept (General priority)

Specific Comments to Authors: This is an article to address Profiling of gene fusion involving targetable genes in Chinese gastric cancer. The authors concluded the

landscape of fusions involving targetable genes in a Chinese GC cohort and found that 1.68% of patients with GC harbor potential targetable gene fusions, which were enriched slightly in patients with ERBB2 amplification. Gene fusion detection may provide a potential treatment strategy for patients with GC with disease progression following standard therapy. That is interesting and helpful. This study contributes to a potential treatment strategy for patients with GC with disease progression following standard therapy.

We thank the reviewer for the positive assessment of our paper.